About Adenylate kinase 8
Adenylate kinase 8 (AK8) is a protein
from Homo sapiens identified by UniProt accession
Q96MA6, 479 residues long.
MolForge cross-references it against 0 known binders and
35 disease associations.
Target properties
| Protein name | Adenylate kinase 8 |
| UniProt accession | Q96MA6 |
| Gene | AK8 |
| Organism | Homo sapiens |
| Length | 479 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (35)
Diseases linked to this target (Open Targets).
- mean corpuscular volume · score 0.35
- Red cell distribution width · score 0.34
- Immature Reticulocyte Fraction Measurement · score 0.30
- mean reticulocyte volume · score 0.30
- mean corpuscular hemoglobin concentration · score 0.30
- mathematical ability · score 0.26
- neuroinflammatory disorder · score 0.22
- mean platelet volume · score 0.21
- lifestyle measurement · score 0.18
- self reported educational attainment · score 0.18
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96MA6-F1 | alphafold | PREDICTED | 87.47 | — |
Amino-acid sequence (479 residues)
MDATIAPHRI PPEMPQYGEE NHIFELMQNM LEQLLIHQPE DPIPFMIQHL HRDNDNVPRI VILGPPASGK TTIAMWLCKH LNSSLLTLEN LILNEFSYTA TEARRLYLQR KTVPSALLVQ LIQERLAEED CIKQGWILDG IPETREQALR IQTLGITPRH VIVLSAPDTV LIERNLGKRI DPQTGEIYHT TFDWPPESEI QNRLMVPEDI SELETAQKLL EYHRNIVRVI PSYPKILKVI SADQPCVDVF YQALTYVQSN HRTNAPFTPR VLLLGPVGSG KSLQAALLAQ KYRLVNVCCG QLLKEAVADR TTFGELIQPF FEKEMAVPDS LLMKVLSQRL DQQDCIQKGW VLHGVPRDLD QAHLLNRLGY NPNRVFFLNV PFDSIMERLT LRRIDPVTGE RYHLMYKPPP TMEIQARLLQ NPKDAEEQVK LKMDLFYRNS ADLEQLYGSA ITLNGDQDPY TVFEYIESGI INPLPKKIP
Explore Adenylate kinase 8 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets